1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow TrueSight Oncology 500: new trials by email Literature Review of TrueSight Oncology 500 trials Research Report on TrueSight Oncology 500
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) LMB-100, pembrolizumab, Mesothelin Expression - Lung Cancer, Non-Small Cell Lung Cancer | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2019-09-11 | 2024-04-16 |
Adenocarcinoma of Lung (1) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1)
National Cancer Institute (NCI) (1)
United States (1)